{"id":59183,"date":"2024-09-09T00:05:05","date_gmt":"2024-09-09T00:05:05","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/09\/09\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/"},"modified":"2024-09-09T00:05:05","modified_gmt":"2024-09-09T00:05:05","slug":"avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/","title":{"rendered":"Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress"},"content":{"rendered":"<div>\n<p align=\"center\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a08 September 2024<\/p>\n<p align=\"center\"><strong>Avacta Group plc<\/strong><\/p>\n<p align=\"center\">(\u201cAvacta\u201d or \u201cthe Group\u201d or \u201cthe Company\u201d)<\/p>\n<p align=\"center\"><strong>Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress <\/strong><\/p>\n<p>Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announces that the company will present updated data from the Phase 1a trial of AVA6000 at the 2024 European Society for Medical Oncology (ESMO) Congress, in Barcelona, Spain from 13-17 September 2024.<\/p>\n<p>The poster presentation will be based on an updated data cut from the Phase 1a trial of AVA6000 in patients with Fibroblast Activation Protein (FAP)-positive solid tumours. AVA6000 is a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by FAP in the tumour microenvironment.<\/p>\n<p>Abstract details are listed below and available online on the ESMO website<strong>. <\/strong><\/p>\n<p><strong>Title:<\/strong> A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released, tumour microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumours\u00a0<br \/><strong>Session Title<\/strong>: Developmental therapeutics <br \/><strong>Session Date and Time:<\/strong> Saturday, September 14, 2024, 9AM CEST time.<br \/><strong>Location: <\/strong>Fira Barcelona Gran Via Av. Joan Carles, Barcelona, Spain<br \/><strong>Abstract Presentation Number:<\/strong> 646P <br \/><strong>First Author: <\/strong>Professor Chris Twelves, University of Leeds<\/p>\n<p align=\"center\"><strong>-Ends-<\/strong><\/p>\n<p align=\"justify\"><strong>For further information from Avacta Group plc, please contact:<\/strong><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><strong>Avacta Group plc<\/strong><\/p>\n<p>Christina Coughlin, CEO<\/p>\n<p>Michael Vinegrad, Group Communications<\/p>\n<p>Director<\/p>\n<p>\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Tel: +44 (0) 1904 21 7070<\/p>\n<p><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eHYWlmlBAg9Z5jL0PuNUn-oM5W8-tZ7G2fKBln7j0deZwKQeS5mddBbBovmA1sLO9fwO4db8P5Bie5G61UAz6w==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.avacta.com\">www.avacta.com<\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \">\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><strong>Peel Hunt (Nomad and Broker)<\/strong><\/p>\n<p>James Steel \/ Chris Golden \/ Patrick Birkholm<\/p>\n<p>\u00a0<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \">\u00a0<\/p>\n<p><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OALvgy6ZgCw1IUQaMWW9i_IagbhBc08ZYlXx5FQmvCGllK4WIXP7s9Sc6x_QHHfDxNqbJBKL2dTJj7J55lw9cQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.peelhunt.com\">www.peelhunt.com<\/a><\/p>\n<p>\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><strong>ICR Consilium<\/strong><\/p>\n<p>Mary-Jane Elliott \/ Jessica Hodgson \/ Sukaina Virji<\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \">\u00a0<\/p>\n<p><a href=\"mailto:avacta@consilium-comms.com\" rel=\"nofollow noopener\" target=\"_blank\" title=\"avacta@consilium-comms.com\">avacta@consilium-comms.com<\/a><\/p>\n<p>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><strong>About Avacta Group plc<\/strong> &#8211;\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sjAj_j6uG087tfOx2sL_uzKFq_stAc73FqDI_aQ2ifMJksm1VKboFMC9j_ZoH4lWPYVFPiGbe5f7Nd9FNQ2XBA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.avacta.com\">www.avacta.com<\/a><\/p>\n<p align=\"justify\">Avacta Group\u00a0is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.<\/p>\n<p align=\"justify\">Avacta Therapeutics: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs.<\/p>\n<p align=\"justify\">Avacta Diagnostics focuses on supporting healthcare professionals and broadening access to diagnostics.<\/p>\n<p align=\"justify\">Avacta has two proprietary platforms, pre|CISION&#x2122; and Affimer<sup>\u00ae<\/sup>.<\/p>\n<p align=\"justify\">The pre|CISION&#x2122; platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumours compared with healthy tissues. The pre|CISION&#x2122; platform harnesses this tumour specific protease to activate pre|CISION&#x2122; peptide drug conjugates and pre|CISION&#x2122; antibody\/Affimer\u00ae drug conjugates in the tumour microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimised to deliver the best outcomes for patients.<\/p>\n<p align=\"justify\">The lead pre|CISION&#x2122; programme AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.<\/p>\n<p align=\"justify\">To register for news alerts by email go to\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sjAj_j6uG087tfOx2sL_u-QBQNMIondNP61BuFUHJmRuqLESynH-8-nYI_l1DgP6-iO9VwmlR43GSAorn4T4648HKxDVEOeqc5FGsc4MUuHjxithdVUKVQ8MIkzUbRMKqSmm3SAZ9vigEHvTEx6aiQ_5-7R0UYpd0lAOlbBX5H0=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.avacta.com\/investor-news-email-alerts\">www.avacta.com\/investor-news-email-alerts<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/MWI1OWZiNWUtOWRhZC00OWM4LWJjNmUtN2U1NDJiMjA4ZWU2LTcwMDAxNDEzNQ==\/tiny\/Avacta-Group.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a08 September 2024 Avacta Group plc (\u201cAvacta\u201d or \u201cthe Group\u201d or \u201cthe Company\u201d) Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announces that the company will present updated [&#8230;]\n","protected":false},"author":1,"featured_media":59184,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-59183","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress\" \/>\n<meta property=\"og:description\" content=\"\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a08 September 2024 Avacta Group plc (\u201cAvacta\u201d or \u201cthe Group\u201d or \u201cthe Company\u201d) Avacta to present updated clinical data on AV\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-09T00:05:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/09\/Avacta-Group.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress\",\"datePublished\":\"2024-09-09T00:05:05+00:00\",\"dateModified\":\"2024-09-09T00:05:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/\"},\"wordCount\":468,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/\",\"name\":\"Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-09-09T00:05:05+00:00\",\"dateModified\":\"2024-09-09T00:05:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/","og_locale":"en_US","og_type":"article","og_title":"Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress","og_description":"\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a08 September 2024 Avacta Group plc (\u201cAvacta\u201d or \u201cthe Group\u201d or \u201cthe Company\u201d) Avacta to present updated clinical data on AV","og_url":"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-09-09T00:05:05+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/09\/Avacta-Group.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress","datePublished":"2024-09-09T00:05:05+00:00","dateModified":"2024-09-09T00:05:05+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/"},"wordCount":468,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/","url":"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/","name":"Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-09-09T00:05:05+00:00","dateModified":"2024-09-09T00:05:05+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical-oncology-esmo-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/59183","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=59183"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/59183\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/59184"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=59183"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=59183"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=59183"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}